Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/24225
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18054/20253 (89%)
造访人次 : 24190513      在线人数 : 534
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/24225


    標題: Rational Design of Novel EGFR Kinase Inhibitors as Anticancer Agents
    作者: Chia-Hsien Wu (吳佳憲)
    Wen-Hsing Lin (林文星)
    John T.A. Hsu (徐祖安)
    Chun-Chen Liao (廖俊臣)
    Yu-Sheng Chao (趙宇生)
    Hsing-Pang Hsieh (謝興邦)
    日期: 2011
    上傳時間: 2011-06-23 14:57:16 (UTC+8)
    摘要: Lung cancer is the first leading cause of death in human carcinoma, with 80- 85% being non-small cell lung cancer (NSCLC). Over-expression of epidermal growth factor receptors (EGFR) is in 40-80% of NSCLC. Gefitinib (Iressa�) and erlotinib (Tarceva�) were approved by FDA as EGFR inhibitors for the treatment of adenocarcinoma (subtype of NSCLC). Gefitinib and erlotinib competitively bind to the ATP binding pocket of EGFR kinase domain and inhibit its activity. These two drugs showed high response rates in Asian NSCLC patients, but patients became resistant to treatment with gefitinib or erlotinib after 6-12 months. Drug resistance occurs as a result of secondary mutation such as T790M mutation. We designed and synthesized novel EGFR- tyrosine kinase inhibitors, which expect to overcome the resistance issues for potential NSCLC therapy. Through hybrid design and knowledge-based design concepts to obtain cmpounds 4, 5, 6 and 7 with 1-9 nM inhibition against wild type EGFR and HCC827 cell-line (EGFR E746-A750 deletion). This series also showed 10-305 nM inhibition against gefitinib-resistant mutant of EGFR (T790M/L858R). More than 200 analogues were synthesized, and the presence of (S)-phenyl-glycinol and Michael acceptor groups are essential for activity in the series of inhibitors.
    關聯: 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會，起迄日：2011/04/06~2011/04/05，地點：溪頭台大實驗林
    显示于类别:[藥理學院] 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會

    文件中的档案:

    档案 描述 大小格式浏览次数
    pp-09.pdf77KbAdobe PDF487检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈